SCHEMBL201943

SCHEMBL201943

CN[C@@H](C(=O)O)C(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21621510 1.00
SCHEMBL31267235 1.00
SCHEMBL201944 1.00
SCHEMBL312336 1.00
SCHEMBL21673293 1.00
SCHEMBL162004 1.00
SCHEMBL162003 1.00
SCHEMBL19080635 1.00
Hydrochloric Acid SCHEMBL1313558 0.97 TP53 (0.43)
SCHEMBL28581240 0.97 TP53 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1974 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 US claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 EP claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 US claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 US disclosed
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE ENTERA BIO LTD. (IL) 2026-05-07 US disclosed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 US disclosed
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-04-23 US disclosed
US-12605425-B2 TNF muteins and uses thereof OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2026-04-21 US disclosed
EP-4710935-A2 NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF Aravax Pty Ltd (AU) 2026-03-18 EP disclosed
WO-1997016202-A1 CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER AMRAD OPERATIONS PTY. LTD. (AU) 1997-05-09 WO disclosed
WO-1997015663-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-05-01 WO disclosed
WO-1997012037-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-04-03 WO disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed